Natixis Advisors’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-179,666
| Closed | -$7.33M | – | 1308 |
|
|
2021
Q1 | $7.33M | Buy |
179,666
+10,603
| +6% | +$432K | 0.04% | 471 |
|
|
2020
Q4 | $7.65M | Sell |
169,063
-15,740
| -9% | -$712K | 0.04% | 427 |
|
|
2020
Q3 | $6.54M | Buy |
184,803
+2,715
| +1% | +$96.1K | 0.04% | 437 |
|
|
2020
Q2 | $6.87M | Buy |
182,088
+16,973
| +10% | +$640K | 0.05% | 409 |
|
|
2020
Q1 | $4.77M | Buy |
165,115
+1,081
| +0.7% | +$31.2K | 0.04% | 465 |
|
|
2019
Q4 | $8.51M | Buy |
164,034
+11,470
| +8% | +$595K | 0.06% | 355 |
|
|
2019
Q3 | $8.37M | Sell |
152,564
-4,995
| -3% | -$274K | 0.07% | 323 |
|
|
2019
Q2 | $6.4M | Buy |
157,559
+101,237
| +180% | +$4.11M | 0.05% | 385 |
|
|
2019
Q1 | $1.7M | Sell |
56,322
-68,658
| -55% | -$2.08M | 0.01% | 808 |
|
|
2018
Q4 | $4.2M | Sell |
124,980
-9,538
| -7% | -$321K | 0.04% | 459 |
|
|
2018
Q3 | $5.67M | Buy |
134,518
+1,842
| +1% | +$77.7K | 0.05% | 419 |
|
|
2018
Q2 | $4.25M | Buy |
132,676
+6,388
| +5% | +$204K | 0.04% | 519 |
|
|
2018
Q1 | $6.28M | Buy |
126,288
+6,835
| +6% | +$340K | 0.06% | 360 |
|
|
2017
Q4 | $6.44M | Buy |
119,453
+5,919
| +5% | +$319K | 0.07% | 344 |
|
|
2017
Q3 | $6.58M | Buy |
113,534
+22,225
| +24% | +$1.29M | 0.07% | 346 |
|
|
2017
Q2 | $4.51M | Buy |
91,309
+3,311
| +4% | +$163K | 0.05% | 465 |
|
|
2017
Q1 | $3.82M | Buy |
+87,998
| New | +$3.82M | 0.04% | 512 |
|